Biochemical Response to Bisphosphonate Therapy in Pagetic Patients with Skull Involvement
Authors:
- 24 July 2006
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 79 (1) , 22-26
Abstract
The aims of this study were to compare the response to therapy in disease activity in pagetic patients with and without skull involvement and the usefulness of bone markers in the evaluation of these patients. Forty patients with Paget’s disease treated with tiludronate and 26 healthy controls were included. Serum total and bone alkaline phosphatases (TAP, BAP), procollagen I N propeptide (PINP), and urinary N- and C-terminal cross-linking telopeptides of collagen I (NTX, α-α CTX, and β-β CTX) were measured at baseline and 6 months after therapy. The extent of the disease was evaluated using the Coutris’ index. Pagetic patients were classified into three groups: patients with skull involvement (G-I, n = 12), patients without skull involvement (G-II, n = 28), and a subgroup of patients from G-II without skull involvement but with similar disease extent to G-I (G-III, n = 10). At baseline, patients from G-I showed significantly higher values in most markers compared to G-II. α-α CTX was the marker with the highest values in all groups. Moreover, monostotic patients with skull involvement showed higher serum baseline values of TAP per unit of affected area than monostotic patients without skull involvement. After therapy, the percentage of patients with markers within the normal range was lower in G-I than in G-II and G-III. In conclusion, pagetic patients with skull involvement showed a marked increase in bone turnover and a lower response to therapy.Keywords
This publication has 22 references indexed in Scilit:
- Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's DiseaseNew England Journal of Medicine, 2005
- Non-Isomerized C-Telopeptide Fragments Are Highly Sensitive Markers for Monitoring Disease Activity and Treatment Efficacy in Paget's Disease of BoneJournal of Bone and Mineral Research, 2005
- Periosteum: biology, regulation, and response to osteoporosis therapiesBone, 2004
- Management of Paget's disease of boneRheumatology, 2004
- Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatmentRheumatology, 2004
- Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potentialBiochemical Journal, 2000
- Decreased β-Isomerization of the C-Terminal Telopeptide of Type I Collagen α1 Chain in Paget's Disease of BoneJournal of Bone and Mineral Research, 1997
- Characterization of Urinary Degradation Products Derived from Type I CollagenJournal of Biological Chemistry, 1997
- Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activityArthritis & Rheumatism, 1997
- Determinants of remission of paget's disease of boneJournal of Bone and Mineral Research, 1993